Medication info

Jaybone Injection (Ibandronate Sodium Trihydrate)

Prescription medicationSolutionIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
JW Pharmaceutical Corporation
Appearance
A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.
Packaging
3mL/prefilled syringe x 1 unit
Approval status
Active

MFDS item code 201501947 · Notified 2015.04.09 · Insurance code 644913971

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; therefore, administration of this medicine is not recommended for these patients. Older adults No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
JW Pharmaceutical Corporation

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis occurring in postmenopausal women. Osteoporosis is a condition where bones become weak and the risk of fractures increases. This drug helps increase bone density and reduce the risk of fractures. Therefore, this medication is used to maintain bone health and prevent fractures in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; therefore, administration of this medicine is not recommended for these patients. Older adults No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication must be administered intravenously, and caution is required as administration into arteries or around veins can cause tissue damage. This drug should not be administered to patients who are allergic to this medication or its components, or to those with untreated hypocalcemia. Using this medication may cause gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation. Additionally, musculoskeletal symptoms such as muscle pain and joint pain have also been reported. Some patients may experience systemic adverse reactions such as influenza-like symptoms, headaches, rashes, and fatigue. During the use of this medication, serum calcium levels may temporarily decrease, so it is important to treat any existing hypocalcemia or bone and mineral metabolism disorders before administration, and to ensure adequate intake of calcium and vitamin D. Patients undergoing dental treatments or those with cancer may have an increased risk of osteonecrosis of the jaw, so it is advisable to have a dental examination before administration and to avoid excessive dental procedures during treatment. Additionally, in rare cases, osteonecrosis of the jaw or external auditory canal has been reported among patients receiving this medication, so caution should be taken if there is pain or discharge from the ear. Long-term use may lead to atypical fractures in the femur or other bones, so if there is pain in the thigh or groin, immediate evaluation is necessary. This medication is excreted by the kidneys; therefore, patients with impaired renal function should undergo regular examinations. Caution is necessary as overdose may affect kidney and liver function. The safety of this medication during pregnancy and lactation has not been established, so it is advisable not to use it. Safety and efficacy in children have not been confirmed, so it is not used in this population. When administering, do not mix with solutions containing calcium, and administer only by intravenous injection. Needles and syringes should not be reused and should be disposed of safely.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • indigestion
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illnesses
Show 56 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reactions
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reactions
  • angioedema
  • facial edema
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • asthma exacerbation
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical subtalar fracture
  • intertrochanteric femoral fracture
  • collateral canal osteonecrosis
  • jaw osteonecrosis
  • sensory loss
  • acute renal failure
  • dizziness
  • optic atrophy
  • lower motor neuron lesions
  • tremor
  • unspecified gastrointestinal diseases
  • benign gastrointestinal neoplasm
  • toothache
  • hyperventilation
  • cough
  • dyspnea
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • multiple organ failure
  • death
  • insomnia
  • anxiety
  • tinnitus
  • hearing loss
  • hypothyroidism
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urinary disorders
  • hematuria
  • skin peeling
  • fracture
  • peripheral neuropathy

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness and safety.

Appearance and packaging

Appearance

A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.

Package unit

3mL/prefilled syringe x 1 unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.